Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors

Leukemia

Volumn 14, Issue 1, 2000, Pages 188-197

  Gu, Z J ^a   De Vos, J ^a   Rebouissou, C ^b   Jourdan, M ^a   Zhang, X G ^a   Rossi, J F ^c   Wijdenes, J ^d   Klein, B ^a,e  

^a INSERM   (France)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d Diaclone   (France)

^e HÔPITAL SAINT ELOI   (France)

Author keywords

Apoptosis; gp130; IL 6; Myeloma; Proliferation

Indexed keywords

GLYCOPROTEIN GP 130; GROWTH FACTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0033971174     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401632     Document Type: Article

References (53)

1. Alexanian R, Dimopoulos MA. Management of multiple myeloma. Semin Hematol 1995; 32: 20-30.
2. Degrassi A, Hibert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 1993; 90: 2060-2064.
3. Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, Poli V. Detective development of pristane-oil-induced plasmacytomas in interleiikin-6-deficient BALB/c mice. Am J Pathol 1997; 151: 689-696.
4. Potter M. Experimental plasmacytomagenesis in mice. Hematol Oncol Clin North Am 1997; 11: 323-347.
5. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863-872.
6. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-3070.
7. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KG. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997; 90: 279-289.
8. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoka H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83-85.
9. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-526.
10. Shimizu S, Yoshioka R, Hirose Y, Susumu S, Tachibana J, Konda S. Establishment of two interleukin-6 (B cell stimulatory factor 2/interferonb2) dependent human bone marrow-derived myeloma cell lines. J Exp Med 1989; 169: 339-344.
11. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654-3663.
12. Westendorf JJ, Ahmann G, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10: 866-876.
13. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334: 297-314.
14. Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R, Kleir B. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994; 179: 1337-1342.
15. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T. Oncostatin M, leukemia inhibitory factor, and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 1994; 179: 1343-1347.
16. Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes J, Rossi JF, Klein B. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996; 88: 3972-3986.
17. Westendorf JJ, Jelinek DF. Growth regulatory pathways in myeloma. Evidence of autocrine oncostatin M expression. J Immunol 1996; 157: 3081-3088.
18. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995; 80: 213-223.
19. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996; 271: 32635-32643.
20. Ward LD, Howlelt GJ, Discolo G, Yasukawa K, Hammacher A, Moritz RL, Simpson RJ. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 1994; 269: 23286-23289.
21. Van Riet I, De Greet C, Aharchi F, Woischwill C, De Waele M, Bakkus M, Lacor P, Schots R, Van Camp B. Establishment and characterization of a human stroma-depenclent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2) Leukemia 1997; 11: 284-293.
22. Bloem AC, Lamme T, de Smet M, Kok H, Vooijs W, Wijdenes J, Boom SE, Lokhorst HM. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines. Br J Haematol 1998; 100: 166-175.
23. Gu ZJ, Wijdenes J, Zhang XG, Hallet MM, Clement C, Klein B. Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. J Immunol Meth 1996; 190: 21-27.
24. Wijdenes J, Heinrich PC, Muller-Newen G, Roche C, Gu ZJ, Clement C, Klein B. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol 1995; 25: 3474-3481.
25. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008-2011.
26. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 1995; 184: 39-51.
27. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vlta N, Laurent P, Sun RX, Klein B, Dore JM. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94: 318-323.
28. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998; 100: 637-646.
29. Sun RX, Lu ZY, Wijdenes J, Brochier J, Hertog C, Rossi JF, Klein B. Large scale and clinical grade purification of syndecan-1-malignant plasma cells. J Immunol Meth 1997; 205: 73-79.
30. Klein B, Zhang XG, Rossi JF. Cytokines, cylokine receptors and signal transduction in human multiple myeloma. In: Malpas JS, Bergsage DE, Kyle RA, Anderson KC (eds). Myeloma: Biology and Management. Oxford University Press: Oxford, 1998, pp 70-88.
31. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15: 797-819.
32. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitan Y, Yamaguchi T, Nakajima K, Hirano T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996; 5: 449-460.
33. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Lovitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
34. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B. Introduction of an activated N-ras oncogene alters the growth characteristics of the interlenkin 6-dependent myeloma cell line ANBL6. Cancer Res 1995; 55: 3640-3646.
35. Neumann C, Zehentmaier G, Danhauser-Riedl S, Emmerich B, Hallek M. Inlerleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1. Eur J Immunol 1996; 26: 379-384.
36. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212-2221.
37. Hallek M, Leif BP, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
38. Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997; 159: 487-496.
39. Ferlin-Bozombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 1998; 161: 2692-2699.
40. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999; 10: 65-70.
41. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260-264.
42. Carey DJ. Syndecans: multifunctional cell-surface co-receplors. Biochem J 1997; 327: 1-16.
43. Pellat-Deceunynck C, Barille S, Puthier D, Rapp MJ, Harousseau JL, Bataille K, Amiot M. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995; 55: 3647-3653.
44. Zhang XG, Olive D, De Vos J, Rebouissou C, Ghiotto-Ragueneau M, Ferlin M, Klein B. Malignant plasma cell lines express a funclional CD28 molecule. Leukemia 1998; 12: 610-618.
45. Pellat D, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge M, Wijdenes J, Amiot M. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597-2603.
46. Campisi J. The biology of replicative senescence. Eur J Cancer 1997; 33: 703-709.
47. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12: 2997-3007.
48. Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, Boccadoro M, Pileri A. Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 1993; 81: 2708-2713.
49. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B and Theillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene 1992; 7: 2539-2543.
50. Urashima M, Teoh G, Ogala A, Chauhan D, Treon SP, Hoshi Y, DeCaprio JA, Anderson KC. Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. Leukemia 1997; 11: 1957-1963.
51. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, Rossi JF, Brochier J, Klein B. A gp130 interleukin-6 transducer-dependent SCID model of human multilple myeloma. Blood 1998; 91: 4727-4737.
52. Autissier P, De Vos J, Liautard J, Tupitsyn N, Jacquet C, Chavdia N, Klein B, Brochier J, Gaillard JP. Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. Int Immunol 1998; 10: 1881-1889.
53. van Dam M, Mullberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L, Heinrich PC, Rose-John S. Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem 1993; 268: 15285-15290.